Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDX
· Real-Time Price · USD
27.34
0.87 (3.29%)
At close: Oct 15, 2025, 3:59 PM
26.91
-1.57%
After-hours: Oct 15, 2025, 04:21 PM EDT
3.29% (1D)
| Bid | 25.67 |
| Market Cap | 1.82B |
| Revenue (ttm) | 5.79M |
| Net Income (ttm) | -199.61M |
| EPS (ttm) | -3.01 |
| PE Ratio (ttm) | -9.08 |
| Forward PE | -6.54 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 29.01 |
| Volume | 960,260 |
| Avg. Volume (20D) | 1,237,804 |
| Open | 26.21 |
| Previous Close | 26.47 |
| Day's Range | 26.10 - 27.73 |
| 52-Week Range | 14.40 - 30.41 |
| Beta | 1.33 |
| Ex-Dividend Date | n/a |
About CLDX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CLDX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CLDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCelldex Therapeutics Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-13.03%
Celldex Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
1 month ago
-1.88%
Celldex Therapeutics shares are trading lower. The company reported Phase 2 topline results for Barzolvolimab in Eosinophilic Esophagitis.
